DOXLIEVA-L 50 MG
Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL
DOXLIEVA-L 50 MG (Doxorubicin Hydrochloride Liposomal Injection 50 mg/25 mL) is a prescription anticancer medicine containing Doxorubicin Hydrochloride 50 mg in a liposomal formulation. It belongs to the Anthracycline class of anticancer medicines and is used in the treatment of several cancers. The liposomal formulation encapsulates doxorubicin within microscopic lipid particles called liposomes. This formulation alters the distribution of the medicine in the body and allows doxorubicin to reach tumor tissues while potentially reducing some of the toxicity associated with conventional doxorubicin. Doxorubicin works primarily by interfering with DNA replication and repair and by inhibiting topoisomerase II, an enzyme required for cancer cell division. It can also generate free radicals that contribute to cancer cell damage. These actions inhibit the growth and multiplication of cancer cells. DOXLIEVA-L 50 MG may be used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma in combination therapy, and certain other cancers, depending on the approved indication and treatment protocol. The medicine is administered by intravenous infusion under the supervision of qualified healthcare professionals experienced in oncology treatment. DOXLIEVA-L 50 MG is commonly used in: Ovarian Cancer AIDS-Related Kaposi's Sarcoma Multiple Myeloma in Combination Therapy Advanced Malignancies Selected Solid Tumors Combination Oncology Treatment Protocols Patients receiving liposomal doxorubicin require regular monitoring of blood counts, liver function, cardiac health, and overall clinical condition.
View Details